{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:13Z","timestamp":1793140333292,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["331065168"],"award-info":[{"award-number":["331065168"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ta434\/3-1"],"award-info":[{"award-number":["Ta434\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1382"],"award-info":[{"award-number":["CRC1382"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ta434\/5-1"],"award-info":[{"award-number":["Ta434\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR57"],"award-info":[{"award-number":["SFB\/TRR57"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jhep.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:47:58Z","timestamp":1588160878000},"page":"757-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":294,"title":["Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-3467","authenticated-orcid":false,"given":"Sander","family":"Lefere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Puengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7050-0797","authenticated-orcid":false,"given":"Jana","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-5785","authenticated-orcid":false,"given":"Christian","family":"Penners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-9986","authenticated-orcid":false,"given":"Adrien","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"de Muynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Adarbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Defr\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Estivalet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Devisscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhep.2020.04.025_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastro Hepat"},{"issue":"1","key":"10.1016\/j.jhep.2020.04.025_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.04.025_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.jhep.2020.04.025_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2020.04.025_bib6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.04.025_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-0036-1571296","article-title":"Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease","volume":"36","author":"Fuchs","year":"2016","journal-title":"Semin Liver Dis"},{"issue":"9","key":"10.1016\/j.jhep.2020.04.025_bib9","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","article-title":"PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein","volume":"50","author":"Maeda","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Moran-Salvador","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1189\/jlb.5RU0116-016R","article-title":"The role of macrophages in obesity-driven chronic liver disease","volume":"99","author":"Devisscher","year":"2016","journal-title":"J\u00a0Leukoc Biol"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.jhep.2020.04.025_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/gutjnl-2019-318382","article-title":"Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis","volume":"69","author":"Krenkel","year":"2020","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jhep.2020.04.025_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cmet.2008.04.002","article-title":"Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity","volume":"7","author":"Kang","year":"2008","journal-title":"Cell Metab"},{"issue":"7148","key":"10.1016\/j.jhep.2020.04.025_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab"},{"issue":"18","key":"10.1016\/j.jhep.2020.04.025_bib18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.jhep.2020.04.025_bib22","doi-asserted-by":"crossref","first-page":"e0184694","DOI":"10.1371\/journal.pone.0184694","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","author":"Puengel","year":"2017","journal-title":"PLoS one"},{"issue":"2","key":"10.1016\/j.jhep.2020.04.025_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.amjcard.2009.03.023","article-title":"Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14)","volume":"104","author":"Spanheimer","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jhep.2020.04.025_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2019.03.016","article-title":"Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers","volume":"71","author":"Lefere","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.04.025_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2017.10.006","article-title":"Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool","volume":"322","author":"Devisscher","year":"2017","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1016\/j.jhep.2020.04.025_bib26","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.04.025_bib27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2020.04.025_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biomaterials.2015.08.043","article-title":"A\u00a0microfluidically perfused three dimensional human liver model","volume":"71","author":"Rennert","year":"2015","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.jhep.2020.04.025_bib29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.04.025_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.cmet.2014.08.010","article-title":"Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages","volume":"20","author":"Kratz","year":"2014","journal-title":"Cell Metab"},{"issue":"13","key":"10.1016\/j.jhep.2020.04.025_bib31","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.celrep.2017.08.096","article-title":"Metabolically activated adipose tissue macrophages perform detrimental and beneficial functions during diet-induced obesity","volume":"20","author":"Coats","year":"2017","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.jhep.2020.04.025_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib33","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cmet.2013.11.001","article-title":"Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation","volume":"18","author":"Xu","year":"2013","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2020.04.025_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2020.04.025_bib36","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.04.025_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2020.04.025_bib38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.30294","article-title":"Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease","volume":"69","author":"Lefere","year":"2019","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820302695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820302695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:54:52Z","timestamp":1777510492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820302695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0168827820302695"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.04.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}